- Raw materials
- Contrast Media
- Ferric ammonium citrate
Ferric ammonium citrate API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ferric ammonium citrate | CAS No: 1185-57-5 | GMP-certified suppliers
A medication that provides bioavailable iron for treating iron deficiency anemia and serves as a paramagnetic contrast agent to enhance MRI imaging quality.
Therapeutic categories
Product Snapshot
- Ferric ammonium citrate is available in oral formulations including granules, effervescent tablets, syrup, liquid, and standard tablets
- It is primarily used as an iron supplement for addressing iron deficiency conditions
- The product is approved for use in the Canadian market and also has experimental status
Clinical Overview
Clinically, ferric ammonium citrate is utilized primarily as an iron source in the treatment and prevention of iron deficiency anemia. It also finds application as a contrast agent in magnetic resonance imaging (MRI), leveraging its paramagnetic properties to enhance image contrast. However, specific approved indications and pharmacodynamic profiles for ferric ammonium citrate are not comprehensively defined in widely available regulatory data.
Mechanistically, as an iron compound, ferric ammonium citrate provides bioavailable ferric ions that participate in hemoglobin synthesis and other iron-dependent physiological processes. Its role as a paramagnetic contrast agent in MRI is attributed to the presence of ferric iron, which influences local magnetic fields and thereby affects image signal characteristics. Detailed mechanistic insights or receptor-level interactions are not extensively described in the current literature.
Key absorption, distribution, metabolism, and excretion (ADME) parameters are not fully characterized for ferric ammonium citrate, though as an iron salt, it is expected to dissociate in the gastrointestinal tract, with iron then absorbed primarily in the duodenum and upper jejunum. The iron undergoes incorporation into systemic iron pools or is stored as ferritin. Metabolic transformation is minimal, and iron elimination occurs mainly through cellular turnover and minor losses via excretion.
Safety considerations include potential risks of iron overload with excessive dosing, which can lead to toxicity particularly involving oxidative stress and organ damage. Hypersensitivity reactions and gastrointestinal irritation can occur. Its use as an MRI contrast agent requires caution in patients with iron metabolism disorders or renal impairment. Monitoring and adherence to recommended dosing are essential to mitigate adverse effects.
Ferric ammonium citrate is available under various formulations and may be included in both approved pharmaceutical products and experimental compounds. When procuring the API, it is important to ensure compliance with pharmacopeial standards and regulatory requirements. Batch consistency, purity, particle size, and absence of contaminants, including microbial and heavy metals, should be thoroughly verified to maintain quality and safety in pharmaceutical manufacturing.
Identification & chemistry
| Generic name | Ferric ammonium citrate |
|---|---|
| Molecule type | Small molecule |
| CAS | 1185-57-5 |
| UNII | UVP74NG1C5 |
| DrugBank ID | DB09501 |
Formulation & handling
- Ferric ammonium citrate is a small molecule iron compound intended for oral administration in various formulations including tablets, syrups, and effervescent granules.
- High water solubility supports formulation as liquid or effervescent dosage forms for improved bioavailability and patient compliance.
- No specific peptide or biologic handling considerations are required; standard protection from moisture and light is recommended to maintain stability.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient (API) entered the market in Canada following patent expiry, allowing for generic competition and contributing to increased market availability. Current market dynamics reflect a mature stage with multiple authorized suppliers. |
|---|
| Markets | Canada |
|---|
Supply Chain
| Supply chain summary | The manufacturing and supply landscape for ferric ammonium citrate in Canada involves multiple originator companies producing branded products such as Deriton, Geritol Liquid, and Heparos Ampoules Buvables, indicating established market players. These brands suggest a presence primarily in the North American region, with limited data on broader US or EU distribution. Patent expiries for this compound typically allow for existing generic competition, supporting a competitive API sourcing environment. |
|---|
Ferric ammonium citrate is a type of Contrast Media
Contrast media, a prominent category in the pharmaceutical API sector, plays a crucial role in medical imaging procedures. These specialized substances enhance the visibility of internal body structures during diagnostic tests such as X-rays, CT scans, and MRIs. By optimizing the contrast between different tissues or organs, contrast media enable healthcare professionals to obtain clearer and more detailed images for accurate diagnosis and treatment planning.
Contrast media can be classified into two main types: iodinated and gadolinium-based. Iodinated contrast agents are commonly used in X-ray and CT examinations, while gadolinium-based agents are employed in MRI scans. Both types are designed to interact with specific imaging technologies and provide contrasting properties to the surrounding tissues.
These pharmaceutical APIs are meticulously developed and undergo rigorous testing to ensure safety and efficacy. They are administered intravenously, orally, or via other routes, depending on the imaging technique and medical requirements. Contrast media are carefully formulated to optimize patient comfort and minimize adverse reactions.
Healthcare providers must consider various factors when selecting contrast media, including the patient's medical history, potential allergies, and the specific imaging procedure. Moreover, ongoing research and technological advancements in contrast media aim to improve image quality, reduce side effects, and enhance patient outcomes.
In summary, contrast media are an essential component of modern medical imaging. Their purpose is to enhance image visibility, aid in accurate diagnosis, and contribute to effective treatment planning. Through continuous advancements and stringent quality control, contrast media continue to play a vital role in improving medical imaging techniques and patient care.
